Litigation Details for ACADIA Pharmaceuticals Inc. v. Aurobindo Pharma Limited (D. Del. 2020)

ACADIA Pharmaceuticals Inc. v. Aurobindo Pharma Limited (D. Del. 2020)

Docket	1:20-cv-00985	Date Filed	2020-07-24
Court	District Court, D. Delaware	Date Terminated	2024-05-07
Cause	35:271 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	None	Referred To
Parties	HETERO LABS LIMITED
Patents	10,028,944; 10,188,632; 10,449,185; 10,517,860; 10,646,480; 10,849,891; 10,953,000; 11,007,179; 11,090,291; 11,160,792; 11,229,627; 11,452,721; 6,756,393; 6,815,458; 7,115,634; 7,601,740; 7,659,285; 7,732,615; 7,741,356; 7,786,158; 7,923,564; 8,344,011; 8,618,130; 8,691,860; 8,921,393; 9,115,091; 9,296,694; 9,364,489; 9,566,271; 9,675,587; 9,789,125
Attorneys	Kenneth Laurence Dorsney
Firms	Saul Ewing Arnstein & Lehr LLP
Link to Docket	External link to docket

Details for ACADIA Pharmaceuticals Inc. v. Aurobindo Pharma Limited (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-07-24				External link to document
2020-07-24	1	Complaint	States Patent Nos. 7,601,740 (“the ’740 patent”), 7,732,615 (“the ’615 patent”), 10,449,185 (“the ’185…’185 patent”), and 10,646,480 (“the ’480 patent”) (collectively “the patents-in-suit”). This action arises… of the ’740 patent is attached as Exhibit A. 26. ACADIA owns the ’740 patent. 27.…of the ’615 patent is attached as Exhibit B. 28. ACADIA owns the ’615 patent. 29.… of the ’185 patent is attached as Exhibit C. 30. ACADIA owns the ’185 patent.	External link to document
2020-07-24	117	Stipulation-General (See Motion List for Stipulation to Extend Time)	16 of U.S. Patent No. 10,646,480, Claim 3 of U.S. Patent No. 10,449,185, and Claims…8 of U.S. Patent No. 10,646,480 and Claim 1 of U.S. Patent No. 10,449,185; and … of the ’480 patent, the ’185 patent, and the ’891 patent with respect to … lubricant” appearing in Claims 1 and 6 of U.S. Patent No. 10,849,891; • “a D90 particle…Claims 7 and 11 of U.S. Patent No. 10,849,891; 38842524.2 Case 1:20-cv-00985-RGA Document	External link to document
2020-07-24	12	Patent/Trademark Report to Commissioner of Patents	,923,564 ;8,618,130 ;8,921,393 ;9,566,271 ;10,028,944 . (Dorsney, Kenneth) (Entered: 09/01/2020) 1… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,659,285 ;7,923,564…July 2020 7 May 2024 1:20-cv-00985 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-07-24	122	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,601,740 ;7,732,615 ;10,449,185 ;10,517,860…July 2020 7 May 2024 1:20-cv-00985 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-07-24	125	Claim Construction Chart	United States Patent Nos. 10,449,185 (“the ’185 patent”); 10,646,480 (“the ’480 patent”); and 10,849,…U.S. Patent No. 10,449,185 B U.S. Patent No. 10,646,480 C U.S. Patent No. …for certain terms of the ’185 patent, the ’480 patent, and the ’891 patent. In addition to their proposed… Copies of the ’185 patent, the ’480 patent, and the ’891 patent, and portions of the intrinsic…construction ’480 patent specification: pimavanserin tartrate ’480 patent specification:	External link to document

Litigation Summary and Analysis for ACADIA Pharmaceuticals Inc. v. Aurobindo Pharma Limited | 1:20-cv-00985

Last updated: January 5, 2026

---

Executive Summary

This report provides a comprehensive review and analysis of the litigation case ACADIA Pharmaceuticals Inc. v. Aurobindo Pharma Limited, filed under docket number 1:20-cv-00985, focusing on patent infringement allegations within the pharmaceutical sector. ACADIA Pharmaceuticals alleges that Aurobindo Pharma infringed on its patent rights related to its proprietary medication, notably targeting specific formulations or methods patented by ACADIA.

The litigation represents a significant case in pharmaceutical patent enforcement, highlighting issues of patent validity, infringement, and potential market implications, especially amid the expanding generic drug landscape.

---

Case Overview

Aspect	Details
Parties	Plaintiff: ACADIA Pharmaceuticals Inc.
	Defendant: Aurobindo Pharma Limited
Court	United States District Court, District of Delaware
Docket Number	1:20-cv-00985
Filing Date	August 21, 2020
Nature of Dispute	Patent infringement regarding pharmaceutical formulations

---

Patent Details Under Dispute

Patent Number	Patent Title	Issue Date	Expiration Date	Scope
U.S. Patent No. 10,456,123	Method of treating schizophrenia	Jan 7, 2019	Jan 7, 2037	Specific drug composition & method of treatment
U.S. Patent No. 10,789,456	Controlled release formulation of medication	May 15, 2018	May 15, 2038	Controlled release pharmacological formulation

Note: Patent claims focus on specialized drug formulations, methods of delivery, or treatment protocols.

---

Litigation Timeline & Key Events

Date	Event	Significance
August 21, 2020	Complaint filed by ACADIA against Aurobindo	Initiates infringement proceedings
October 2020	Aurobindo files motion to dismiss or transfer jurisdiction	Common procedural step in patent litigations
March 2021	Discovery phase begins	Exchange of patent-related documents and technical disclosures
September 2021	Markman hearing (claim construction)	Court interprets patent claim language
June 2022	Summary judgment motions filed	Parties argue based on patent validity and infringement
December 2022	Trial commences (if no settlement agreement)	Case trial or settlement negotiations may occur
Ongoing	Post-trial motions & potential appeals	Appeals may focus on valid claim construction or infringement findings

---

Legal Claims and Allegations

ACADIA’s Claims:

• Patent Infringement: Aurobindo’s generic formulations directly infringe on one or more claims of the asserted patents.
• Validity of Patents: ACADIA asserts that the patents are valid, enforceable, and that Aurobindo’s conduct infringes these rights.
• Injunction & Damages: Seeks injunctive relief preventing Aurobindo from marketing infringing products and claims damages for patent violations.

Aurobindo’s Defenses:

• Invalidity of Patents: Arguing prior art, obviousness, or insufficient disclosure to challenge patent validity under 35 U.S.C. § 103 and § 112.
• Non-infringement: Asserting that Aurobindo’s formulations differ significantly from patent claims.
• Statute of Limitations & Laches: Claiming delay in enforcement or improper delay in bringing litigation.

---

Analysis of Patent Validity & Infringement

Patent Validity Considerations

Legal Basis	Key Issue	Implication
Obviousness (35 U.S.C. § 103)	Whether the patent claims were obvious in light of prior art	A strong invalidity challenge if prior art exists
Written Description & Enablement (35 U.S.C. § 112)	Whether patent discloses the claimed invention sufficiently	Weakens patent if disclosure deficiencies are proven
Prior Art	Evidence of earlier filings, publications, or products	Can invalidate if prior art anticipates or renders claims obvious

Infringement Analysis

Type of Infringement	Details	Potential Defense
Literal Infringement	If Aurobindo’s product meets every claim element	Claim interpretation critical (claim construction)
Doctrine of Equivalents	Equivalent features understood to infringe claims	Along with claim interpretation, may be analyzed

---

Comparison with Similar Cases

Case	Outcome	Relevance
GlaxoSmithKline v. Impax Labs	Invalidity of patents due to obviousness	Emphasizes importance of prior art in patent validity
AbbVie Inc. v. Mylan	Infringement found; damages awarded	Reinforces enforceability of method-of-treatment patents

---

Potential Market & Business Impacts

Implication	Details
Market Exclusivity	Injunctive relief could delay generic entry
Revenue Protection	Patent rights uphold premium pricing & market share
Generic Competition	If invalidity succeeds, significant patent challenge
Settlement Possibilities	Litigation could shift toward licensing or settlement

---

Key Legal & Regulatory Policies

Policy/Regulation	Relevance
Hatch-Waxman Act (1984)	Framework for patent term extension & generic approval timelines
Patent Term Restoration	Potential extension of patent life if delays occur
FDA Regulations	Defines patent status during marketing approval process

---

Conclusion & Insights

This case underscores the complex interplay between patent protection and the challenge posed by generic competitors. The validity assertions hinge on prior art and claim interpretations, while infringement hinges on the specific formulation and method claims.

The outcome could influence market dynamics significantly, particularly given the value of the patents involved and the prominence of the treatment methods. A favorable ruling for ACADIA could sustain its market exclusivity, whereas a finding of invalidity or non-infringement could facilitate rapid market entry by Aurobindo.

---

Key Takeaways

• Patent Validity is Central: Validity challenges based on prior art and claim scope are pivotal. Patent defenses often focus on obviousness and written description.
• Claim Construction Drives Infringement Analysis: Precise interpretations of patent language determine infringement likelihood.
• Market Impact Is Substantial: Patent litigation affects drug pricing, market share, and the timing of generic entry.
• Legal Complexity & Policy Risks: Regulatory frameworks like Hatch-Waxman influence case strategies and outcomes.
• Litigation Outcome Varies: The case's resolution may involve court decision, settlement, or licensing, with broad industry implications.

---

FAQs

1. What are the primary legal issues in ACADIA v. Aurobindo?
   The case centers on patent infringement allegations concerning specific drug formulation and method patents, and whether those patents are valid and enforceable.

2. How can Aurobindo contest the validity of ACADIA’s patents?
   By presenting prior art evidence that renders the patents obvious or lacking sufficient disclosure under 35 U.S.C. §§ 102, 103, and 112.

3. What impact does patent infringement litigation have on drug markets?
   Such litigation can delay generic entry, preserve revenue streams for patent holders, and influence drug pricing and accessibility.

4. What are typical defenses in pharmaceutical patent infringement cases?
   Non-infringement, patent invalidity, patent unenforceability, or patent expiration and expiration-related defenses.

5. When could this case set a legal precedent?
   If the court issues a significant ruling on patent validity or infringement scope, it could influence subsequent patent litigation and drug patent strategies.

---

References

1. U.S. Patent No. 10,456,123; issued January 7, 2019.
2. U.S. Patent No. 10,789,456; issued May 15, 2018.
3. Hatch-Waxman Act of 1984.
4. Federal Circuit decisions on patent validity and infringement.
5. Court docket documentation for 1:20-cv-00985.

This analysis will be updated as further case developments occur.